Gland Pharma Wins USFDA Nod for Generic Depo-Medrol Injection
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Gland Pharma wins USFDA approval for generic Methylprednisolone Acetate Injectable Suspension, equal to Pfizer’s Depo-Medrol, a USD 214 million US market.
Dr Reddy’s wins USFDA tentative approval under PEPFAR for generic twice-yearly lenacapavir for HIV prevention, with first supplies due before end-2026.
India’s pharmaceutical exports grew 4.90% to USD 16.14 billion in April–September 2026, Pharmexcil data shows. Q2 exports rose 3.05% to USD 8.04 billion, Europe climbed 9.66% to USD 3.29 billion, ASEAN rose 21.54% and bulk drugs grew 12.07%, while US shipments moderated.
Strides Pharma Science grew Q2 FY27 revenue 17% to ₹1,429.7 crore. Ex-US markets rose 31% to ₹696 crore, passing the US business (₹686 crore, +9%) in quarterly revenue for the first time, while EBITDA crossed ₹250 crore and margins eased to 17.6%.
Senores Pharmaceuticals will expand capacity at its US subsidiary Havix from 1.2 billion to 2 billion units a year and at Apnar Pharma in India from 0.5 billion to 1.2 billion units, and add a 2.7 million-unit prefilled syringe line at Ratnatris, for an estimated ₹43 crore by March 2027.
Indoco Remedies’ Hyderabad-headquartered contract research arm AnaCipher has secured ANVISA approval for its clinical and bioanalytical facilities after a March–April 2026 inspection, clearing it to run bioavailability and bioequivalence studies for Brazilian regulatory submissions, a gateway to Latin America’s largest pharma market.
The Indian Patent Office has rejected TB Alliance’s patent application for BPaL, the six-month bedaquiline-pretomanid-linezolid regimen for drug-resistant TB, after two pre-grant oppositions argued the combination lacked an inventive step, a decision patient groups say could open the door to generic competition and lower prices.
About 17% of USFDA inspections at Indian pharma facilities now end with an Official Action Indicated classification, up from 11% in 2024, India Ratings says, warning that tougher scrutiny could delay approvals as US sales of Indian drugmakers soften.